SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Infinity Pharmaceuticals
INFI 0.0160-4.8%Sep 29 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (80)8/28/2006 11:43:46 PM
From: Mike McFarland  Read Replies (1) of 210
 
The Serenex slide I pointed to awhile back has something
about elevated rat liver enzymes, diarrhea, and
thrombocytopenia (what the devil is that) for 17dmag, fwiw.

Maybe Infinity's competition is Serenex?
(and Kosan, Astex, Synta, Arqule, Neutec, Vernalis)

Are you caffeinated this evening Tuck, I can't keep
up with you. It is no wonder I had to give up
trading. But this buy and hold approach is for the dogs <g>

<googling "Nereus polyketide" and "Kosan polyketide" and behold the difference>

The best I can do is point to the article I posted on
the Nereus thread. So yeah, I guess I am reaching.

"bryostatin isolated from the bryozoan Bugula neritina, does
not superficially resemble any microbial product, it is a
complex polyketide. Complex polyketides (non-aromatic
macrolides) are typically produced by bacteria and fungi,
and hence, it was suggested that bryostatin is produced by a
microbial symbiont of the bryozoan"
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext